Download PDF
Dtsch Med Wochenschr 2011; 136(22): 1165-1168
DOI: 10.1055/s-0031-1280531
Endokrinologie und Diabetologie | Commentary
Endokrinologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen

New therapeutic options for advanced thyroid cancerM. J. Willhauck1 , M. Schott2 , M. C. Kreissl3 , M. Fassnacht4 , C. Spitzweg1
  • 1Medizinische Klinik und Poliklinik II – Campus Großhadern, Klinikum der Universität München, Ludwig-Maximilians-Universität München
  • 2Klinik für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
  • 3Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg
  • 4Medizinische Klinik und Poliklinik I, Schwerpunkt Endokrinologie – Diabetologie, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg
Further Information

Publication History

Publication Date:
24 May 2011 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Schilddrüsenkarzinom - Multityrosinkinase-Inhibitoren - Sorafenib - Sunitinib - Vandetanib

Keywords

thyroid cancer - multi-tyrosine kinase inhibitors - sorafenib - sunitinib - vandetanib

Literatur

  • 1 Bible K C, Suman V J, Molina J R. et al . Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers.  Lancet Oncol. 2010;  11 962-972
    Google Scholar
  • 2 Carr L L, Mankoff D A, Goulart B H. et al . Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.  Clin Cancer Res. 2010;  16 5260-5268
    Google Scholar
  • 3 Cohen E EW, Needles B M, Cullen K J. et al . Phase 2 study of sunitinib in refractory thyroid cancer.  J Clin Oncol. 2008;  26 (Suppl.) Abstract 6025
    Google Scholar
  • 4 Cohen E EW, Rosen L S, Vokes E E. et al . Axitinib is an active traetment for all histologic subtypes of advanced thyroid cancer.  J Clin Oncol. 2008;  26 4708-4713
    Google Scholar
  • 5 De Souza J A, Busaidy N, Zimrin A. et al . Phase II trial of sunitinib in medullary thyroid cancer (MTC).  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5504
    Google Scholar
  • 6 Gupta-Abramson V, Troxel A B, Nellore A. et al . Phase II trial of sorafenib in advanced thyroid cancer.  J Clin Oncol. 2008;  26 4714-4719
    Google Scholar
  • 7 Hoftijzer H, Heemastra K A, Morreau H. et al . Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.  Eur J Endocrinol. 2009;  161 923-931
    Google Scholar
  • 8 Kloos R T, Ringel M D, Knopp M V. et al . Phase II trial of sorafenib in metastatic thyroid cancer.  J Clin Oncol. 2009;  27 1675-1684
    Google Scholar
  • 9 Kurzrock R, Cohen E E, Sherman S I. et al . Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL 184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5502
    Google Scholar
  • 10 Lam E T, Ringel M D, Kloos R T. et al . Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.  J Clin Oncol. 2010;  28 2323-2330
    Google Scholar
  • 11 Ravaud A, de la Fouchardiere C, Courbon F. et al . Sunitinib in patients with refractory advanced thyroid cancer.  J Clin Oncol. 2008;  26 Suppl Abstract 6058
    Google Scholar
  • 12 Robinson B G, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.  J Clin Endocrinol Metab. 2010;  95 2664-2671
    Google Scholar
  • 13 Schlumberger M, Elisei R, Bastholt L. et al . Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.  J Clin Oncol. 2009;  27 3794-3801
    Google Scholar
  • 14 Sherman S I, Wirth L J, Droz J -P. et al . Motesanib diphosphate in progressive differentiated thyroid cancer.  New Engl J Med. 2008;  359 31-42
    Google Scholar
  • 15 Wells S A, Gosnell J E, Gagel R F. et al . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.  J Clin Oncol. 2010;  28 767-772
    Google Scholar
  • 16 Wells S A, Robinson B G, Gagel R F. et al . Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC).  J Clin Oncol. 2010;  28 (Suppl.) Abstract 5503
    Google Scholar
  • 17 Woyach J A, Shah M H. New therapeutic advances in the management of progressive thyroid cancer.  Endocrine Rel Cancer. 2009;  16 715-731
    Google Scholar

Prof. Dr. Christine Spitzweg

Medizinische Klinik und Poliklinik II
Klinikum der Universität München – Campus Großhadern

Marchioninistr. 15

81377 München

Phone: 089/7095-0

Fax: 089/7095-8887

Email: Christine.Spitzweg@med.uni-muenchen.de

      >